Actions and spectrum:
upadacitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1. JAKs are intracellular enzymes involved in the JAK-STAT signaling pathway, which is important in immune cell signaling and activation.
By inhibiting JAK1, upadacitinib interferes with the activity of multiple cytokines, including interleukin (IL)-2, IL-4, IL-6, IL-7, IL-9, IL-15, and IL-21, which are involved in immune and inflammatory responses.
upadacitinib is used for the treatment of several autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
